Media Centre

The Therapeutic Goods Administration (TGA) has recognised disinfectants as critical in preventing the spread of COVID-19¹. Diversey Australia and New Zealand are proud to announce Taskforce J-Fill® has gained approval for the label claim ‘Kills SARS-CoV-2 (COVID-19 virus)’ under ARTG 334780.
“With the new TGA COVID-19 label claim on Taskforce J-Fill, our product range continues to grow, servicing our valued customers at this unprecedented time. As a global company, Diversey continues to work tirelessly in product development, sourcing and testing to assist in controlling the spread of COVID-19.” Said Wayne Hill, Managing Director, Diversey ANZ.
For use in Diversey’s Quattro Select dispensing system, Taskforce J-Fill is a cleaner and disinfectant for use on all washroom hard surfaces. Kills SARS-CoV-2 (COVID-19 virus). When used as directed Taskforce J-Fill provides disinfecting action on hard surfaces, as well as providing concentrated cleaning power. Leaves a
pleasant long-lasting fragrance.
“As cases of COVID-19 grow, the demand and urgency for cleaning and disinfection requirements has reached unprecedented levels. It was important we worked with the Australian TGA to add the COVID-19 claim to our range of products. It was also important we communicate this information to our valued customers. Whilst we
celebrate this announcement, our stock level challenges persist due to unprecedented demands. We ask for patience as we service multiple essential services including healthcare and aged care facilities”. Noted Debbie Walker, Marketing Manager ANZ.
Diversey has been, and always will be, a pioneer and facilitator for life. We constantly deliver revolutionary cleaning and hygiene technologies that provide total confidence to our customers across all of our global sectors.

For more information on contact:
Diversey Australia
Healthcare Sector Lead: David Purnell
Phone: 0411 075 732 or email This email address is being protected from spambots. You need JavaScript enabled to view it.
29 Chifley Street, Smithfield NSW 2164 AUSTRALIA
Diversey New Zealand
Healthcare Sector Lead: Hazel Wright
Phone: 064 21 853 161 or email This email address is being protected from spambots. You need JavaScript enabled to view it.
24 Bancroft Cres, Glendene, Auckland, NEW ZEALAND
diversey.com

The Therapeutic Goods Administration (TGA) has recognised disinfectants as critical in preventing the spread of COVID-19¹. Following our previous announcement that Oxivir^® Tb had gained TGA approval for a COVID-19 label claim, Diversey Australia and New Zealand are proud to announce Oxivir^® Five 16 and Virex^® II are now approved with the label claim ‘Kills SARS-CoV-2 (COVID-19 virus)’. This new claim is in addition to the current comprehensive list of claims under ARTG 286618 for Oxivir^® Five 16 and ARTG 153031 for Virex II. 

“We are pleased to announce our Oxivir Five 16 and Virex II ranges have now gained TGA approval for a claim to kill COVID-19. This added claim offers confidence to our valued customers during this uncertain time. As a global company, Diversey continues to work tirelessly in product development, sourcing and testing to assist in controlling the spread of COVID-19.” Said Wayne Hill, Managing Director, Diversey ANZ.

Diversey Australia and New Zealand are proud to announce Oxivir^® Tb (Accelerated Hydrogen Peroxide^® (AHP^®) based formulation) is now approved with the label claim “Kills SARS-CoV-2 (COVID-19 virus) in 1 minute”. This new claim is in addition to the current comprehensive list of virucidal, bactericidal and fungicidal claims under ARTG 164850 for Oxivir Tb Wipes, standard, large, refill wipes and ARTG 165058 for Oxivir Tb Ready to Use (RTU) Liquid.

“As a global leader in the cleaning and hygiene industry Diversey Australia is working tirelessly to supply our valued customers with products which assist to limit the spread of COVID-19. I would like to extend my gratitude to our ANZ Technical team who have gained TGA approvals to add this additional claim against COVID-19. This claim brings greater confidence to the various sectors we service including Healthcare, Hospitality, BSC and Retail.” Said Wayne Hill, Managing Director, Diversey ANZ. 

Overview: The outbreak in Wuhan China of a newly identified coronavirus (colloquially the Wuhan Coronavirus) has raised questions about how various disinfectants will perform against this new virus when tested in standardized testing or when used in real-world applications. This document discusses our current understanding of these questions.

Disinfectant Testing: In the United States, disinfectants are tested for efficacy against pathogenic organisms using standardized methods approved by the United States Environmental Protection Agency (US-EPA). In Europe, EN standardized tests are used for the same purpose. These testing methods are developed to standardize evaluation of the performance of a chemical disinfectant against pathogenic microorganisms.

Multilevel approaches to cleaning and disinfection, using solutions such as AHP, contribute to better health outcomes for hospital patients, aged care residents, staff and visitors.

Gastroenteritis can be costly in terms of reputation, productivity, staff health and patient outcomes. When it comes to infection, prevention is better than cure.

How good are they really?

Disinfectant wipes are the fastest growing packaging format globally for disinfectants. When compared to traditional cleaning methods, wipes decrease the time to clean patient rooms by 23% and they reduce the human capital cost by around $50 per employee per day. Disinfectant wipes also significantly increase cleaning and disinfection compliance (Weimken 2014).

Why do infection rates peak in some hospitals and not others? How can we best manage HAIs?

By: Ivan Obreza

Chlorine bleach has long been the standard chemical for Clostridium difficile  disinfection. Unfortunately, whilst efficacious, bleach is also corrosive. New  technologies are emerging that do not sacrifice safety for efficacy. And they  are redefining the way we view powerful disinfection chemistry. Sporicide  Plus™ belongs to the classification of strong disinfectants called sporicidals.  They are specifically designed to kill bacterial spores such as C. diff without  the risks associated with bleach.

There is no easy way to clean a hospital or aged care facility and keep it clean, regardless of how we define "clean." This article (Australian Hospital and Healthcare Bulletin, Spring 2017) explores the reasons for variability in cleaning practice from one facility to another.

Best practice cleaning and disinfection is an evolving paradigm. The attached link opens an article that was published in The Australian Hospital and Healthcare Bulletin (Winter 2017).

Hospital cleaning and disinfection: What is best practice?

We understand the issues and challenges that hospitals and aged care facilities face during the cold and flu season and the impact it has on patients, residents and staff.  

At Diversey, we have provided proven infection prevention solutions to major hospitals and aged care facilities in Australia and New Zealand for over 30 years.

Killing Environmental C. difficile spores

Clostridium difficile has emerged as a substantial antimicrobial-resistant threat to healthcare, with a mortality rate in Australia of 5%. Environmental disinfection using the right product, process and proof of compliance, is critical. Sporicide Plus™ is a novel disinfectant that finally addresses the age old dichotomy: choosing a powerful disinfectant that kills bacterial spores but has a good safety profile.

Healthcare Cleaning and Disinfection –

What is best practice?

The new strain of the most common cause of viral gastroenteritis norovirus, has been detected in Victoria and health experts warn it could become an epidemic.

The new strained referred to as Melbourne Norovirus, is expected to radiate out of Victoria into New South Wales and Queensland, then peak in all states in mid 2017.